SITE014-0126

SITE014 (NLD) › SITE014-0126

SITE014-0126

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-01-27

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 121); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.